ArticleOncology and therapy2026

First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307.

Zhijie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.